Carisma Therapeutics, Inc.
CARM
$0.237
$0.01124.96%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | 31.89% | 37.49% | 30.39% | 22.82% | 8.90% |
Total Depreciation and Amortization | -38.57% | -39.29% | 18.22% | 20.82% | 18.07% |
Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | -100.00% |
Total Other Non-Cash Items | -11.11% | -2.99% | 30.49% | 56.39% | 54.66% |
Change in Net Operating Assets | 103.02% | 20.40% | -119.87% | -63.29% | -694.76% |
Cash from Operations | 50.63% | 39.08% | 26.19% | 17.67% | -8.83% |
Capital Expenditure | 100.00% | 89.55% | 89.13% | 23.15% | 70.94% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -85.65% | -12.29% |
Cash from Investing | -98.29% | -99.45% | -100.17% | -86.39% | -8.26% |
Total Debt Issued | -100.00% | -100.00% | -42.01% | -70.23% | -67.91% |
Total Debt Repaid | 49.78% | 54.52% | -15.53% | -41.85% | -190.30% |
Issuance of Common Stock | -95.57% | -95.57% | -92.30% | -89.88% | -90.19% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -100.00% | -102.51% |
Cash from Financing | -236.69% | 61.19% | -99.45% | -98.24% | -100.81% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -6.50% | -675.19% | -211.77% | -203.80% | -198.19% |